---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-023130"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-27T00:21:30.911901+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics pauses BEACON-IPF Phase 2b trial of bexotegrast after DSMB review

## Summary
- Voluntarily paused enrollment and dosing in BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis (IPF).
- Pause follows prespecified data review and recommendations by independent Data Safety Monitoring Board (DSMB).
- Patients currently enrolled in the trial will remain and be monitored while data is reviewed; blinding maintained.
- Company has informed trial investigators and is in process of informing global regulatory authorities.
- No details provided on DSMB rationale; lead asset trial halt likely materially negative for PLRX stock.

## SEC filing metadata
- accession: 0001193125-25-023130
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000119312525023130/0001193125-25-023130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000119312525023130/d931376d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-023130
- JSON: https://secwatch.observer/filing/0001193125-25-023130.json
- Plain text: https://secwatch.observer/filing/0001193125-25-023130.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.